CN Patent

CN110898067A — 癌症治疗方法

Assigned to Epizyme Inc · Expires 2020-03-24 · 6y expired

What this patent protects

本发明涉及通过向有需要的受试者投与EZH2抑制剂化合物和医药组合物来治疗癌症的方法。本发明还涉及所述化合物用于研究或其它非治疗性目的的用途。

USPTO Abstract

本发明涉及通过向有需要的受试者投与EZH2抑制剂化合物和医药组合物来治疗癌症的方法。本发明还涉及所述化合物用于研究或其它非治疗性目的的用途。

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: CN110898067A
Jurisdiction: CN
Classification: —
Expires: 2020-03-24
Drug substance claim: No
Drug product claim: No
Assignee: Epizyme Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.